ARTICLE | Emerging Company Profile
Aprinoia tackles tau
How Aprinoia is targeting tauopathies via imaging tracers, mAbs, small molecules
September 21, 2018 10:29 PM UTC
Aprinoia Therapeutics Inc. is developing a pipeline targeting tauopathies that includes diagnostic imaging tracers, mAbs specific to pathologic tau and small molecules that bind to tau rather than dissociate tau aggregates.
“We are going to develop imaging biomarkers for all the therapeutic targets first to see those targets, and then find therapies,” CEO Ming-Kuei Jang told BioCentury. ...
BCIQ Company Profiles
BCIQ Target Profiles